lomustine has been researched along with Neutropenia in 16 studies
Neutropenia: A decrease in the number of NEUTROPHILS found in the blood.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Temozolomide is an alkylating agent with activity in the treatment of melanoma metastatic to the brain." | 9.12 | A phase I/II study of lomustine and temozolomide in patients with cerebral metastases from malignant melanoma. ( Bate, SC; Beirne, DA; Eisen, TG; Gibbens, IM; Gore, ME; Hughes, SA; Larkin, JM; Patel, PM; Thomas, K, 2007) |
| "A prospective phase II study of paclitaxel was performed in adult patients with recurrent hemispheric oligodendrogliomas." | 9.08 | Salvage chemotherapy with paclitaxel for recurrent oligodendrogliomas. ( Chamberlain, MC; Kormanik, PA, 1997) |
| "40 patients with symptomatic metastatic melanoma were treated with procarbazine, vincristine and lomustine (POC)." | 9.07 | Phase II trial of procarbazine, vincristine and lomustine (POC) chemotherapy in metastatic cutaneous malignant melanoma. ( Evans, BD; Harvey, VJ; Mak, D; Melville, P; Mitchell, PL; Samuel, LM; Thompson, PI, 1994) |
| "Multi-agent chemotherapy (vincristine, epirubicin and prednisolone) including either cyclophosphamide (CEOP) or lomustine (LEOP) was given as first-line chemotherapy to treatment-naïve canine lymphoma patients with measurable, high grade T-cell lymphoma (HGTCL)." | 7.91 | A Retrospective Study of Multi-agent Chemotherapy including either Cyclophosphamide or Lomustine as Initial Therapy for Canine High-grade T-cell Lymphoma (2011-2017). ( Baines, S; Elliott, J, 2019) |
| " All patients required dosage modification for toxicity." | 5.28 | Results of treatment of children with recurrent medulloblastoma/primitive neuroectodermal tumors with lomustine, cisplatin, and vincristine. ( Evans, AE; Lefkowitz, IB; Packer, RJ; Schut, L; Siegel, KR; Sutton, LN, 1990) |
| "Temozolomide is an alkylating agent with activity in the treatment of melanoma metastatic to the brain." | 5.12 | A phase I/II study of lomustine and temozolomide in patients with cerebral metastases from malignant melanoma. ( Bate, SC; Beirne, DA; Eisen, TG; Gibbens, IM; Gore, ME; Hughes, SA; Larkin, JM; Patel, PM; Thomas, K, 2007) |
| "A prospective phase II study of paclitaxel was performed in adult patients with recurrent hemispheric oligodendrogliomas." | 5.08 | Salvage chemotherapy with paclitaxel for recurrent oligodendrogliomas. ( Chamberlain, MC; Kormanik, PA, 1997) |
| "40 patients with symptomatic metastatic melanoma were treated with procarbazine, vincristine and lomustine (POC)." | 5.07 | Phase II trial of procarbazine, vincristine and lomustine (POC) chemotherapy in metastatic cutaneous malignant melanoma. ( Evans, BD; Harvey, VJ; Mak, D; Melville, P; Mitchell, PL; Samuel, LM; Thompson, PI, 1994) |
| "Multi-agent chemotherapy (vincristine, epirubicin and prednisolone) including either cyclophosphamide (CEOP) or lomustine (LEOP) was given as first-line chemotherapy to treatment-naïve canine lymphoma patients with measurable, high grade T-cell lymphoma (HGTCL)." | 3.91 | A Retrospective Study of Multi-agent Chemotherapy including either Cyclophosphamide or Lomustine as Initial Therapy for Canine High-grade T-cell Lymphoma (2011-2017). ( Baines, S; Elliott, J, 2019) |
| "Lomustine is a commercially available chloroethyl nitrosourea compound whose antitumor activity in vitro and in animal tumor models exceeds its activity in humans." | 2.67 | A phase I trial of weekly lomustine in patients with advanced cancer. ( Benjamin, RS; Gorski, CC; Koller, CA; Legha, SS; Papadopoulos, NE; Plager, C, 1994) |
| "Neutropenia was documented in 20 dogs (57%): 12 grade I to II, 8 grade III to IV." | 1.48 | Evaluation of a multi-agent chemotherapy protocol combining lomustine, procarbazine and prednisolone (LPP) for the treatment of relapsed canine non-Hodgkin high-grade lymphomas. ( Amores-Fuster, I; Blackwood, L; Finotello, R; Harper, A; Killick, DR; Maddox, TW; Mason, SL; Tanis, JB, 2018) |
| " All patients required dosage modification for toxicity." | 1.28 | Results of treatment of children with recurrent medulloblastoma/primitive neuroectodermal tumors with lomustine, cisplatin, and vincristine. ( Evans, AE; Lefkowitz, IB; Packer, RJ; Schut, L; Siegel, KR; Sutton, LN, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (37.50) | 18.2507 |
| 2000's | 5 (31.25) | 29.6817 |
| 2010's | 5 (31.25) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tanis, JB | 1 |
| Mason, SL | 1 |
| Maddox, TW | 1 |
| Blackwood, L | 1 |
| Killick, DR | 1 |
| Amores-Fuster, I | 1 |
| Harper, A | 1 |
| Finotello, R | 1 |
| Elliott, J | 1 |
| Baines, S | 1 |
| Intile, JL | 2 |
| Rassnick, KM | 2 |
| Bailey, DB | 2 |
| Al-Sarraf, R | 1 |
| Chretin, JD | 1 |
| Balkman, CE | 2 |
| Flory, AB | 2 |
| Kiselow, MA | 2 |
| Wakshlag, JJ | 1 |
| Russell, DS | 1 |
| Malone, EK | 1 |
| Barnard, SM | 1 |
| Heading, KL | 1 |
| Brockley, LK | 1 |
| Bennett, PF | 1 |
| Abrams-Ogg, AC | 1 |
| Larkin, JM | 1 |
| Hughes, SA | 1 |
| Beirne, DA | 1 |
| Patel, PM | 1 |
| Gibbens, IM | 1 |
| Bate, SC | 1 |
| Thomas, K | 1 |
| Eisen, TG | 1 |
| Gore, ME | 1 |
| Samuel, LM | 1 |
| Harvey, VJ | 1 |
| Mitchell, PL | 1 |
| Thompson, PI | 1 |
| Mak, D | 1 |
| Melville, P | 1 |
| Evans, BD | 1 |
| Koller, CA | 1 |
| Gorski, CC | 1 |
| Benjamin, RS | 1 |
| Legha, SS | 1 |
| Papadopoulos, NE | 1 |
| Plager, C | 1 |
| Sweetenham, JW | 1 |
| McKendrick, JJ | 1 |
| Mead, GM | 1 |
| Whitehouse, JM | 1 |
| Chamberlain, MC | 1 |
| Kormanik, PA | 1 |
| Abele, M | 1 |
| Leonhardt, M | 1 |
| Dichgans, J | 1 |
| Weller, M | 1 |
| Parameswaran, R | 1 |
| Giles, C | 1 |
| Boots, M | 1 |
| Littlewood, TJ | 1 |
| Mills, MJ | 1 |
| Kelsey, SM | 2 |
| Samson, D | 1 |
| Shamash, J | 1 |
| Walewski, J | 1 |
| Apostolidis, J | 1 |
| Wilson, AM | 1 |
| Foran, JM | 1 |
| Gupta, RK | 1 |
| Rohatiner, AZ | 1 |
| Lister, TA | 1 |
| Noël, G | 1 |
| Mazeron, JJ | 1 |
| Lefkowitz, IB | 1 |
| Packer, RJ | 1 |
| Siegel, KR | 1 |
| Sutton, LN | 1 |
| Schut, L | 1 |
| Evans, AE | 1 |
6 trials available for lomustine and Neutropenia
| Article | Year |
|---|---|
A phase II study to evaluate the toxicity and efficacy of alternating CCNU and high-dose vinblastine and prednisone (CVP) for treatment of dogs with high-grade, metastatic or nonresectable mast cell tumours.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Agents, | 2010 |
A phase I/II study of lomustine and temozolomide in patients with cerebral metastases from malignant melanoma.
Topics: Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarb | 2007 |
Phase II trial of procarbazine, vincristine and lomustine (POC) chemotherapy in metastatic cutaneous malignant melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Lomustine; Male; Melano | 1994 |
A phase I trial of weekly lomustine in patients with advanced cancer.
Topics: Administration, Oral; Adult; Aged; Capsules; Carcinoma, Renal Cell; Drug Administration Schedule; Dr | 1994 |
Salvage chemotherapy with paclitaxel for recurrent oligodendrogliomas.
Topics: Adult; Alopecia; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; | 1997 |
Low-dose continuous chemotherapy (LBCMVD-56) for refractory and relapsing lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Chlorambucil; De | 2000 |
10 other studies available for lomustine and Neutropenia
| Article | Year |
|---|---|
Evaluation of a multi-agent chemotherapy protocol combining lomustine, procarbazine and prednisolone (LPP) for the treatment of relapsed canine non-Hodgkin high-grade lymphomas.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Dog Diseases; Dogs; Female; Lomustine; Lymp | 2018 |
A Retrospective Study of Multi-agent Chemotherapy including either Cyclophosphamide or Lomustine as Initial Therapy for Canine High-grade T-cell Lymphoma (2011-2017).
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Horm | 2019 |
Evaluation of dexamethasone as a chemoprotectant for CCNU-induced bone marrow suppression in dogs.
Topics: Animals; Antineoplastic Agents, Alkylating; Bone Marrow; Dexamethasone; Dog Diseases; Dogs; Dose-Res | 2009 |
CCNU (lomustine) toxicity in dogs: a retrospective study (2002-07).
Topics: Anemia; Animals; Antineoplastic Agents, Alkylating; Dog Diseases; Dogs; Female; Gastrointestinal Dis | 2011 |
The use of lithium carbonate to prevent lomustine-induced myelosuppression in dogs: a pilot study.
Topics: Animals; Antidepressive Agents; Antineoplastic Agents, Alkylating; Dog Diseases; Dogs; Dose-Response | 2011 |
Prednisolone, cytosine arabinoside, lomustine (CCNU), etoposide and thioguanine (PACET) combination chemotherapy for relapsed or refractory non-Hodgkin lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Humans; | 1993 |
CCNU overdose during PCV chemotherapy for anaplastic astrocytoma.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neo | 1998 |
CCNU (lomustine), idarubicin and dexamethasone (CIDEX): an effective oral regimen for the treatment of refractory or relapsed myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Anti | 2000 |
[Post-operative neoadjuvant chemotherapy before radiotherapy as compared to immediate radiotherapy followed by maintenance chemotherapy in the treatment of medulloblastoma in childhood: results of German prospective randomised trial HIT'91].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemotherapy, Adjuvant; | 2001 |
Results of treatment of children with recurrent medulloblastoma/primitive neuroectodermal tumors with lomustine, cisplatin, and vincristine.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Cerebellar Neoplasms; Child; Child, Pres | 1990 |